Laboratory Medicine ›› 2021, Vol. 36 ›› Issue (1): 101-106.DOI: 10.3969/j.issn.1673-8640.2021.01.021
Previous Articles Next Articles
JIANG Yaping1(), XU Guobing2, LIU Ou3
Received:
2019-05-12
Online:
2021-01-30
Published:
2021-02-05
CLC Number:
JIANG Yaping, XU Guobing, LIU Ou. Preparation of five frozen pooled human serum samples as secondary reference materials for uric acid[J]. Laboratory Medicine, 2021, 36(1): 101-106.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2021.01.021
仪器型号 | 试剂 | 校准品 | 质控品 | |||||
---|---|---|---|---|---|---|---|---|
生产者 | 批号 | 生产者 | 批号 | 生产者 | 批号 | |||
Roche Modular P | Roche | 635694 | Roche | 153318 | Roche cfas. | 170066 | ||
Roche Modular P | Roche | 639781 | Roche | 155208 | Roche cfas. | 170066 | ||
Roche Modular D | Roche | 638054 | Roche | 171683 | Roche cfas. | 170066 | ||
Roche cobas 8000 | Roche | 640909 | Roche | 155211 | Roche cfas. | 170066 | ||
Beckman AU5800 | Beckman-Coulter | AUZ6556 | Beckman-Coulter | 1121H | 朗道 | HN1530、HE1532 | ||
Dade RXL-MAX | Dade | GB1144 | Dade | OCD030 | 朗道 | HN1530、HE1532 | ||
Ortho-Vitros FS | Ortho | 241799 | Ortho | 0149 | Ortho | F2271、E2067 | ||
Ortho-Vitros 5600 | Ortho | 242913 | Ortho | 0150 | Ortho | F2271、E2067 | ||
Ortho-Vitros 350 | Ortho | 241779 | Ortho | 0150 | Ortho | F2271、E2067 | ||
Ortho-Vitros 950 | Ortho | 242684 | Ortho | 0150 | Ortho | F2271、E2067 | ||
Hitachi 7600 | Wako | KF087、EN775 | Wako | EE602 | 朗道 | 374UN、224UE | ||
Hitachi 7180 | Wako | KF087、EN775 | Wako | EE602 | 朗道 | 611UN、354UE | ||
迪瑞CS-600B | Reebio(宁波瑞源) | 2019062401 | Reebio | 2019052301 | 朗道 | HN1530,HE1532 | ||
迈瑞BS-430 | 中元 | 190602 | 朗道 | 1029UE | 朗道 | 1293UN、1007UE | ||
迪瑞CS-380 | 迪瑞 | 20190123 | 迪瑞 | 20180921 | 朗道 | 1293UN、1007UE |
仪器型号 | 试剂 | 校准品 | 质控品 | |||||
---|---|---|---|---|---|---|---|---|
生产者 | 批号 | 生产者 | 批号 | 生产者 | 批号 | |||
Roche Modular P | Roche | 635694 | Roche | 153318 | Roche cfas. | 170066 | ||
Roche Modular P | Roche | 639781 | Roche | 155208 | Roche cfas. | 170066 | ||
Roche Modular D | Roche | 638054 | Roche | 171683 | Roche cfas. | 170066 | ||
Roche cobas 8000 | Roche | 640909 | Roche | 155211 | Roche cfas. | 170066 | ||
Beckman AU5800 | Beckman-Coulter | AUZ6556 | Beckman-Coulter | 1121H | 朗道 | HN1530、HE1532 | ||
Dade RXL-MAX | Dade | GB1144 | Dade | OCD030 | 朗道 | HN1530、HE1532 | ||
Ortho-Vitros FS | Ortho | 241799 | Ortho | 0149 | Ortho | F2271、E2067 | ||
Ortho-Vitros 5600 | Ortho | 242913 | Ortho | 0150 | Ortho | F2271、E2067 | ||
Ortho-Vitros 350 | Ortho | 241779 | Ortho | 0150 | Ortho | F2271、E2067 | ||
Ortho-Vitros 950 | Ortho | 242684 | Ortho | 0150 | Ortho | F2271、E2067 | ||
Hitachi 7600 | Wako | KF087、EN775 | Wako | EE602 | 朗道 | 374UN、224UE | ||
Hitachi 7180 | Wako | KF087、EN775 | Wako | EE602 | 朗道 | 611UN、354UE | ||
迪瑞CS-600B | Reebio(宁波瑞源) | 2019062401 | Reebio | 2019052301 | 朗道 | HN1530,HE1532 | ||
迈瑞BS-430 | 中元 | 190602 | 朗道 | 1029UE | 朗道 | 1293UN、1007UE | ||
迪瑞CS-380 | 迪瑞 | 20190123 | 迪瑞 | 20180921 | 朗道 | 1293UN、1007UE |
标准物质 | 瓶间变异/% | MSamong | MSwithin | P值 | ubb/ (μmol/L) |
---|---|---|---|---|---|
C1 | 0.72 | 0.459 | 0.267 | 0.149 | 0.253 |
C2 | 0.39 | 1.930 | 0.900 | 0.075 | 0.586 |
C3 | 0.38 | 3.337 | 1.433 | 0.055 | 0.797 |
C4 | 0.44 | 4.978 | 2.900 | 0.150 | 0.832 |
C5 | 0.47 | 8.389 | 5.200 | 0.178 | 1.031 |
标准物质 | 瓶间变异/% | MSamong | MSwithin | P值 | ubb/ (μmol/L) |
---|---|---|---|---|---|
C1 | 0.72 | 0.459 | 0.267 | 0.149 | 0.253 |
C2 | 0.39 | 1.930 | 0.900 | 0.075 | 0.586 |
C3 | 0.38 | 3.337 | 1.433 | 0.055 | 0.797 |
C4 | 0.44 | 4.978 | 2.900 | 0.150 | 0.832 |
C5 | 0.47 | 8.389 | 5.200 | 0.178 | 1.031 |
保存时间 | C1 | C2 | C3 | C4 | C5 |
---|---|---|---|---|---|
0个月 | 77.5 | 284.0 | 382.5 | 424.0 | 511.0 |
1个月 | 77.5 | 283.5 | 380.0 | 423.5 | 508.0 |
1.5个月 | 76.5 | 284.0 | 375.5 | 420.5 | 503.0 |
2个月 | 76.0 | 285.0 | 381.5 | 424.0 | 513.5 |
4个月 | 78.0 | 281.0 | 379.5 | 420.5 | 505.0 |
5个月 | 76.5 | 282.0 | 376.5 | 421.5 | 501.0 |
7个月 | 77.0 | 282.5 | 380.5 | 423.5 | 510.0 |
9个月 | 77.5 | 283.5 | 381.0 | 423.0 | 510.0 |
11个月 | 76.5 | 284.0 | 381.0 | 422.5 | 511.5 |
13个月 | 77.5 | 285.0 | 379.5 | 424.0 | 510.0 |
15个月 | 76.5 | 282.0 | 381.0 | 424.5 | 510.5 |
P值 | 0.806 | 0.799 | 0.626 | 0.329 | 0.402 |
ults(15个月) | 0.615 | 1.245 | 2.010 | 1.305 | 3.600 |
保存时间 | C1 | C2 | C3 | C4 | C5 |
---|---|---|---|---|---|
0个月 | 77.5 | 284.0 | 382.5 | 424.0 | 511.0 |
1个月 | 77.5 | 283.5 | 380.0 | 423.5 | 508.0 |
1.5个月 | 76.5 | 284.0 | 375.5 | 420.5 | 503.0 |
2个月 | 76.0 | 285.0 | 381.5 | 424.0 | 513.5 |
4个月 | 78.0 | 281.0 | 379.5 | 420.5 | 505.0 |
5个月 | 76.5 | 282.0 | 376.5 | 421.5 | 501.0 |
7个月 | 77.0 | 282.5 | 380.5 | 423.5 | 510.0 |
9个月 | 77.5 | 283.5 | 381.0 | 423.0 | 510.0 |
11个月 | 76.5 | 284.0 | 381.0 | 422.5 | 511.5 |
13个月 | 77.5 | 285.0 | 379.5 | 424.0 | 510.0 |
15个月 | 76.5 | 282.0 | 381.0 | 424.5 | 510.5 |
P值 | 0.806 | 0.799 | 0.626 | 0.329 | 0.402 |
ults(15个月) | 0.615 | 1.245 | 2.010 | 1.305 | 3.600 |
物质 | 北京大学 第一医院 (RP-HPLC-UV) | 中生北控 (RP-HPLC-UV) | 临检中心 (ID-LC/MS/MS) | 3家x | 3家s | ubb | ults | uCRM | 靶值±uCRM |
---|---|---|---|---|---|---|---|---|---|
C1 | 69.00±1.15 | 71.00±1.26 | 70.00±1.71 | 70.00 | 1.41 | 0.253 | 0.615 | 3.12 | 70.00±3.12 |
C2 | 281.00±1.00 | 282.00±2.75 | 282.00±1.71 | 281.67 | 1.90 | 0.586 | 1.245 | 4.69 | 281.67±4.69 |
C3 | 383.00±3.06 | 384.00±1.41 | 382.00±2.99 | 383.00 | 2.40 | 0.797 | 2.010 | 6.46 | 383.00±6.46 |
C4 | 431.00±4.58 | 431.00±4.65 | 431.00±6.24 | 431.00 | 4.73 | 0.832 | 1.305 | 9.95 | 431.00±9.95 |
C5 | 521.00±4.93 | 517.00±3.50 | 522.00±4.92 | 520.00 | 4.75 | 1.031 | 3.600 | 12.10 | 520.00±12.10 |
物质 | 北京大学 第一医院 (RP-HPLC-UV) | 中生北控 (RP-HPLC-UV) | 临检中心 (ID-LC/MS/MS) | 3家x | 3家s | ubb | ults | uCRM | 靶值±uCRM |
---|---|---|---|---|---|---|---|---|---|
C1 | 69.00±1.15 | 71.00±1.26 | 70.00±1.71 | 70.00 | 1.41 | 0.253 | 0.615 | 3.12 | 70.00±3.12 |
C2 | 281.00±1.00 | 282.00±2.75 | 282.00±1.71 | 281.67 | 1.90 | 0.586 | 1.245 | 4.69 | 281.67±4.69 |
C3 | 383.00±3.06 | 384.00±1.41 | 382.00±2.99 | 383.00 | 2.40 | 0.797 | 2.010 | 6.46 | 383.00±6.46 |
C4 | 431.00±4.58 | 431.00±4.65 | 431.00±6.24 | 431.00 | 4.73 | 0.832 | 1.305 | 9.95 | 431.00±9.95 |
C5 | 521.00±4.93 | 517.00±3.50 | 522.00±4.92 | 520.00 | 4.75 | 1.031 | 3.600 | 12.10 | 520.00±12.10 |
检测系统 | 相关方程式 | 相关 系数 | 95% 可信区间 | C1/ (μmol/L) | C2/ (μmol/L) | C3/ (μmol/L) | C4/ (μmol/L) | C5/ (μmol/L) |
---|---|---|---|---|---|---|---|---|
Roche Modular P | Y=0.957X-3.327 | 0.999 | 0.947~0.967 | 62.5 | 272.4 | 372.3 | 412.7 | 500.0 |
Roche Modular P | Y=0.956X-3.212 | 0.999 | 0.946~0.967 | 62.5 | 272.4 | 373.3 | 412.7 | 501.0 |
Roche Modular D | Y=0.957X-3.441 | 0.999 | 0.947~0.968 | 62.5 | 272.4 | 371.3 | 412.7 | 499.0 |
Roche cobas 8000 | Y=0.975X-9.753 | 0.999 | 0.960~0.990 | 66.0 | 270.0 | 370.0 | 416.0 | 509.0 |
Beckman-Coulter AU5800 | Y=0.907X+16.341 | 0.999 | 0.895~0.919 | 77.5 | 280.5 | 380.0 | 420.0 | 502.0 |
Dade RXL-MAX | Y=0.971X-9.545 | 0.999 | 0.959~0.983 | 60.0 | 262.0 | 354.0 | 401.0 | 499.0 |
Ortho-Vitros FS | Y=0.971X+9.865 | 0.999 | 0.960~0.982 | 71.1 | 282.5 | 383.1 | 431.4 | 519.4 |
Ortho-Vitros 5600 | Y=0.973X+8.424 | 0.999 | 0.962~0.984 | 71.2 | 282.8 | 384.1 | 432.7 | 519.8 |
Ortho-Vitros 350 | Y=0.969X+11.306 | 0.999 | 0.956~0.981 | 71.0 | 282.2 | 382.0 | 430.0 | 519.0 |
Ortho-Vitros 950 | Y=0.974X+7.861 | 0.999 | 0.963~0.984 | 71.4 | 283.1 | 383.6 | 431.9 | 520.1 |
Hitachi 7600 | Y=0.982X+5.530 | 0.999 | 0.971~0.993 | 67.5 | 283.5 | 390.0 | 428.5 | 522.0 |
Hitachi 7180 | Y=0.980X+5.578 | 0.999 | 0.969~0.992 | 66.0 | 285.0 | 390.0 | 427.0 | 520.0 |
迪瑞CS-600B | Y=0.983X+5.483 | 0.999 | 0.971~0.995 | 69.0 | 282.0 | 390.0 | 427.0 | 520.0 |
迈瑞BS-430 | Y=0.903X+17.123 | 0.999 | 0.889~0.917 | 77.0 | 280.0 | 379.0 | 427.0 | 508.0 |
迪瑞CS-380 | Y=0.904X+18.033 | 0.999 | 0.889~0.918 | 78.0 | 281.0 | 381.0 | 421.0 | 521.0 |
检测系统 | 相关方程式 | 相关 系数 | 95% 可信区间 | C1/ (μmol/L) | C2/ (μmol/L) | C3/ (μmol/L) | C4/ (μmol/L) | C5/ (μmol/L) |
---|---|---|---|---|---|---|---|---|
Roche Modular P | Y=0.957X-3.327 | 0.999 | 0.947~0.967 | 62.5 | 272.4 | 372.3 | 412.7 | 500.0 |
Roche Modular P | Y=0.956X-3.212 | 0.999 | 0.946~0.967 | 62.5 | 272.4 | 373.3 | 412.7 | 501.0 |
Roche Modular D | Y=0.957X-3.441 | 0.999 | 0.947~0.968 | 62.5 | 272.4 | 371.3 | 412.7 | 499.0 |
Roche cobas 8000 | Y=0.975X-9.753 | 0.999 | 0.960~0.990 | 66.0 | 270.0 | 370.0 | 416.0 | 509.0 |
Beckman-Coulter AU5800 | Y=0.907X+16.341 | 0.999 | 0.895~0.919 | 77.5 | 280.5 | 380.0 | 420.0 | 502.0 |
Dade RXL-MAX | Y=0.971X-9.545 | 0.999 | 0.959~0.983 | 60.0 | 262.0 | 354.0 | 401.0 | 499.0 |
Ortho-Vitros FS | Y=0.971X+9.865 | 0.999 | 0.960~0.982 | 71.1 | 282.5 | 383.1 | 431.4 | 519.4 |
Ortho-Vitros 5600 | Y=0.973X+8.424 | 0.999 | 0.962~0.984 | 71.2 | 282.8 | 384.1 | 432.7 | 519.8 |
Ortho-Vitros 350 | Y=0.969X+11.306 | 0.999 | 0.956~0.981 | 71.0 | 282.2 | 382.0 | 430.0 | 519.0 |
Ortho-Vitros 950 | Y=0.974X+7.861 | 0.999 | 0.963~0.984 | 71.4 | 283.1 | 383.6 | 431.9 | 520.1 |
Hitachi 7600 | Y=0.982X+5.530 | 0.999 | 0.971~0.993 | 67.5 | 283.5 | 390.0 | 428.5 | 522.0 |
Hitachi 7180 | Y=0.980X+5.578 | 0.999 | 0.969~0.992 | 66.0 | 285.0 | 390.0 | 427.0 | 520.0 |
迪瑞CS-600B | Y=0.983X+5.483 | 0.999 | 0.971~0.995 | 69.0 | 282.0 | 390.0 | 427.0 | 520.0 |
迈瑞BS-430 | Y=0.903X+17.123 | 0.999 | 0.889~0.917 | 77.0 | 280.0 | 379.0 | 427.0 | 508.0 |
迪瑞CS-380 | Y=0.904X+18.033 | 0.999 | 0.889~0.918 | 78.0 | 281.0 | 381.0 | 421.0 | 521.0 |
[1] | LI Z J,YI C J,LI J,et al.Serum uric acid level as a cardio-cerebrovascular event risk factor in middle-aged and non-obese Chinese men[J]. Oncotarget,2017,8(15):24110-24118. |
[2] | REN Y,GAO L,GUO X,et al.Interactive effect of serum uric acid and total bilirubin for micro-vascular disease of type 2 diabetes in China[J]. J Diabetes Complications,2018,32(11):1000-1005. |
[3] | ZHENG R,YANG T,CHEN Q,et al.Serum uric acid concentrations can predict hypertension:a longitudinal population-based epidemiological study[J]. Horm Metab Res,2017,49(11):873-879. |
[4] | CIBIKOVÁ,LANGOVÁ K,VAVERKOVÁ H,et al. Correlation of uric acid levels and parameters of metabolic syndrome[J]. Physiol Res,2017,66(3):481-487. |
[5] | International Organization for Standardization. Reference materials-general and statistical principles for certification[S]. ISO Guide 35,ISO,2006. |
[6] | 日本臨床化学会学術連絡委員会. HPLCを用いる血清尿酸測定の勧告法[J]. 臨床化学,1993,22(4):300-307. |
[7] | 江雅平,刘欧,徐国宾,等. 反相高效液相色谱紫外法检测人血清尿酸[J]. 临床检验杂志,2012,30(4):244-248. |
[8] | National Committee for Clinical Laboratory Standards. Evaluation of matric effects;Approved guideline,2nd ed[S]. EP14-A2,NCCLS,2005. |
[9] | JIANG Y,LIU O,XU G.Assessment of the trueness and inter-laboratory precision of routine uric acid assays using 4 frozen pooled serum samples measured by the Japan Society of Clinical Chemistry's HPLC Method[J]. Ann Lab Med,2014,34(2):104-110. |
[10] | MILLER W G,MYERS G L,ASHWOOD E R,et al.State of the art in trueness and interlaboratory harmonization for 10 analytes in general clinical chemistry[J]. Arch Pathol Lab Med,2008,132(5):838-846. |
[1] | LIN Feiran, OU Yuanzhu, LIU Wenbin, YU Xiaoxuan, GE Danhong, ZHAO Ran. Influence of different-brand calibrators on the comparability of serum alkaline phosphatase determination results [J]. Laboratory Medicine, 2022, 37(2): 183-187. |
[2] | ZHANG Chen, LI Ting, MENG Qinghao, XIE Nan, ZHANG Weimin, ZHAO Fei, LI Min, GAO Xuan, YANG Sijie. Performance evaluation of glycerol as stabilizer for the preparation of seminal plasma biochemical quality control products [J]. Laboratory Medicine, 2022, 37(12): 1200-1203. |
[3] | SUN Jiangman, MENG Xiangzhao, LI Min, SHAO Yan, YU Hongyuan. Optimization of serum uric acid reference measurement proceduce and application in conventional systems [J]. Laboratory Medicine, 2022, 37(10): 984-988. |
[4] | WANG Jianbing, HAN Liqiao, LIN Haibiao, ZHANG Qiaoxuan, YAN Jun, ZHUANG Junhua, HUANG Xianzhang. Production of candidate secondary reference material for catalytic activity concentration of alpha-amylase in frozen human serum [J]. Laboratory Medicine, 2021, 36(3): 255-258. |
[5] | DNA XU Mingyong, ZHU Huaqiang, WU Yonghua, ZHUANG Lidong. Preparation and evaluation of the quality control materials of Chlamydia trachomatis [J]. Laboratory Medicine, 2021, 36(1): 107-110. |
[6] | MA Zhengyao, GUO Wei, PAN Baishen, WANG Beili. Relationship between serum uric acid and red blood cell parameters in hyperuricemia patients [J]. Laboratory Medicine, 2019, 34(6): 486-490. |
[7] | CHEN Miaomiao, GUO Lin, LU Renquan. Research progress of COPS5 in tumors [J]. Laboratory Medicine, 2019, 34(2): 98-102. |
[8] | YU Ting, SHEN Min, SUN Nan, QU Shoufang, HUANG Jie. Development of national standard materials of urea,uric acid and total protein in compound frozen human serum [J]. Laboratory Medicine, 2018, 33(8): 755-759. |
[9] | JIN Zhonggan, JU Yi, LI Qing, TANG Liping, YU Xiaoxuan, LIU Wenbin, OU Yuanzhu. Analysis on the results of creatinine,uric acid and urea determination trueness verification in Shanghai,2016 [J]. Laboratory Medicine, 2018, 33(4): 348-352. |
[10] | CHEN Shiwei, YE Zhicheng, FU Pan, LI Wei, YANG Dan, XU Jin. Reference ranges of biochemical determination items for children's kidney function in Shanghai [J]. Laboratory Medicine, 2018, 33(10): 884-887. |
[11] | WANG Gangqiang, CHENG Xiang, ZHENG Shanluan. Stability of routine urine dry chemical method in 24 h [J]. Laboratory Medicine, 2017, 32(9): 818-821. |
[12] | XU Liyuan, YING Chunmei. Establishment of reference intervals for renal function parameters in middle and late pregnancy [J]. Laboratory Medicine, 2017, 32(8): 682-685. |
[13] | LI Jiangfeng, FENG Minyi, QIAN Wei, ZHAO Xiaoni, CHEN Zitong, JIAO Liyuan, WANG Jihua, CAI Lei. Preparation and performance of recombinant human cystatin C quality control material [J]. Laboratory Medicine, 2017, 32(8): 733-737. |
[14] | SHI Jianxin, ZHU Yan, JIANG Ying, XIANG Yingjun, LIN Huiling, DUAN Guikai. Preparation and performance evaluation of quality control material for homocysteine [J]. Laboratory Medicine, 2017, 32(4): 343-346. |
[15] | LIANG Jianwei, MU Sicong, ZHOU Wei, LI Wansha, LI Jian, ZHANG Jing, CHEN Xi, CHEN Xinyu, SHAN Quanzhong. Influence of indoor CO2 concentration on the stability of CO2 reagents by enzymatic method [J]. Laboratory Medicine, 2017, 32(10): 844-848. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||